WGO Graded Evidence: Diverticular Disease

Level: Clinical Trials: 7 Abstracts

Legend:   : Special Mention  : Important  : Very Important  : Key Development
	Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. A Tursi, G Brandimarte, GM Giorgetti, W Elisei, Dig Dis Sci. 2007 Mar:671-4
	Interaction between rifaximin and dietary fibre in patients with diverticular disease. R D'Incà, F Pomerri, MG Vettorato, E Dal Pont, V Di Leo, A Ferronato, V Medici, GC Sturniolo, Aliment Pharmacol Ther. 2007 Apr 1:771-9
	Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. G Comparato, L Fanigliulo, LG Cavallaro, G Aragona, GM Cavestro, V Iori, M Maino, G Mazzocchi, P Muzzetto, G Colla, M Sianesi, A Franzé, FD Mario, Dig Dis Sci. 2007 Nov:2934-41
Supplementary evidence:
	Efficacy of mesalazine in the treatment of symptomatic diverticular disease. F Di Mario, G Aragona, G Leandro, G Comparato, L Fanigliulo, LG Cavallaro, GM Cavestro, V Iori, M Maino, AM Moussa, A Gnocchi, G Mazzocchi, A Franzé, Dig Dis Sci. 2005 Mar:581-6
	Laparoscopic approach to treatment of sigmoid diverticulitis: changes in the spectrum of indications and results of a prospective, multicenter study on 1,545 patients. H Scheidbach, C Schneider, J Rose, J Konradt, E Gross, E Bærlehner, M Pross, U Schmidt, F K&oeig;ckerling, H Lippert, Dis Colon Rectum. 2004 Nov:1883-8
	Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. G Latella, MT Pimpo, S Sottili, M Zippi, A Viscido, M Chiaramonte, G Frieri, Int J Colorectal Dis. 2003 Jan:55-62
	The LAPDIV-CAMIC Study. Multicenter prospective randomized study of short-term and intermediate-term outcome of laparoscopic and conventional sigmoid resection in diverticular disease W Schwenk, LAPDIV-CAMIC-Studiengruppe, Chirurg. 2004 Jul:706-7